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Abstract: Psoriasis is a chronic, genetically determined, immune-mediated, inflammatory 
skin disease affecting approximately 2% to 3% of Caucasian population. Given the well-
established role of the immuno-mediated inflammation in the pathogenesis of psoriasis, in 
the past few years several key steps in the pathogenesis of this disease have been elucidated 
and the increased knowledge led to the development of specific drugs, commonly defined 
as “biologics” targeting one or more of these steps. At present an anti-CD11a antibody 
(efalizumab), an anti-LFA3/CD2 receptor (alefacept) and 3 antitumor necrosis factor alpha 
agents (adalimumab, etanercept, infliximab) are now commercially available for the treatment 
of both psoriasis and psoriatic arthritis. Recent studies have demonstrated that interleukins 
(IL) 12 and 23 play an important role in the pathophysiology of psoriasis. In fact members 
of the IL-12 family of cytokines have the potential to act as the next major cytokine(s) in 
pathogenesis and the treatment of psoriasis. Ustekinumab (CNTO 1275, Centocor Inc, Malvern, 
PA, USA) is a human monoclonal antibody that binds to the shared p40 protein subunit of 
human interleukins 12 and 23 with high affinity and specificity, thereby preventing interaction 
with their surface IL-12Rβ1 receptor. Different clinical studies have been conducted to date. In 
particular a phase II study and two phase III studies, PHOENIX 1 together with PHOENIX 2, 
show very encouraging results. This review reports on the latest progress made in the clinical 
use of biologic drugs for psoriasis focusing on the new human IL-12/23 monoclonal antibody, 
ustekinumab, for psoriasis.
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Introduction
Psoriasis is a chronic, genetically determined, immuno-mediated, inflammatory skin 
disease1 affecting approximately 2% to 3% of Caucasian population.2 Plaque type is 
the most common form,3,4 prevalence ranging between 5% and 42%, and depending 
on the population studied, psoriatic arthritis may occur.5 In the majority of patients 
(70%) psoriasis is present for several years before arthritis onset; in 10% to 15% 
arthritis precedes psoriasis, while in 15% the initial presentation includes arthritis 
and psoriasis together.6,7 Psoriasis can be associated with significant psychological 
morbidity, comparable with that of major medical illnesses such as rheumatoid 
arthritis, hypertension, heart disease and depression.8,9 Furthermore, an alarmingly 
higher percentage of depression and suicidal ideation has been observed in psoriatic 
populations compared to other severe diseases in the absence of a correct philosophy 
counseling.10–12 Numerous co-morbidities, such as dyslipidemia, heart disease, 
hypertension, diabetes and emphysema have been reported.13Clinical, Cosmetic and Investigational Dermatology 2009:2 96
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This review reports on the latest progress made in the 
clinical use of biologic drugs for psoriasis, focusing on the 
new human IL 12/23 monoclonal antibody, ustekinumab, 
for psoriasis.
Overview of antipsoriatic agents
The choice of treatment for psoriasis depends on the severity 
of the disease. However, the evaluation of its severity may be 
difficult in some cases, as not only objective parameters (eg, 
extension, erythema, infiltration) but also the impact on the 
quality of life of the patients must be taken into consideration. 
Indeed smaller lesions may cause higher psychological 
or physical discomfort for the patient, depending on their 
localization.
Given the well-established role of the immuno-mediated 
inflammation in the pathogenesis of psoriasis, the immune 
system is the main target of almost all systemic treatments 
available for this disease.
Systemic agents, including ciclosporin, methotrexate and 
acitretine, or phototherapy are usually prescribed in patients 
affected by moderate to severe plaque-type psoriasis or 
psoriatic arthritis. However, various factors may limit their 
long-term use, in particular the risk of serious cumulative organ 
toxicity14 and the lack of efficacy over time.15 Furthermore, 
underlying diseases, such as hypertension as well as renal 
and/or hepatic alterations, may represent contraindications 
to the above-mentioned systemic treatments. Thus, effective 
drugs with less long-term toxicity are needed.
An excellent therapeutic improvement has been recently 
obtained by the introduction of the “biological response 
modifiers”, or more commonly defined as “biologics”. 
Biologics are a heterogeneous group of monoclonal 
antibodies, fusion proteins and recombinant cytokines, 
designed to modify and regulate pivotal and specific 
mechanisms involved in psoriasis immunopathogenesis. To 
date, biologics have been suggested to have a more favorable 
side effect profile than conventional treatments.16
Biologic agents for the treatment 
of psoriasis
Psoriasis can be considered as the prototype chronic 
inflammatory disorder. In the past few years several key 
steps in the pathogenesis of this disease have been elucidated 
and the increased knowledge has led to the development of 
specific drugs targeting one or more of these steps.
Recent literature17 indicates the activation of the innate 
immune system as the initial factor triggering psoriasis. 
Genetically determined defects in the skin barrier (eg, PSORS4 
and PSORS6) lead to the activation of skin resident 
plasmocytoid dendritic cells by antimicrobial peptides such as 
cathelicidin (LL37) or beta-defensin 2 induced by saprophytic 
flora or trauma. These cells, belonging to the innate branch 
of the immune system, overproduce inflammatory cytokines 
such as IFNa, LTa and IL1β which in turn activate CD11c 
expressing myeloid dendritic cells.18
The activation of these cells appears to be a key step in 
psoriasis plaque initiation. Indeed CD11c positive myeloid 
dendritic cells (also called dermal dendritic cells) are capable 
of activating naïve-T lymphocytes in lymph nodes and to 
induce their polarization to Th1 or Th17 cells.18 Production of 
two specific heterodimeric cytokines (interleukins 12 and 23, 
IL-12 and IL-23) which share a common subunit (p40) are 
necessary to direct T-cells toward the Th1 (IL-12) or Th17 
(IL-23) phenotype.
Activated T lymphocytes are then subjected to a cell 
trafficking/homing step, involving the interaction between 
leucocyte function-assisted antigen-1 (LFA1) and ICAM1 
molecules, which directs them towards inflamed skin. Once 
in the inflamed site T-cells are reactivated by dermal dendritic 
cells and produce a specific set of cytokines including antitumor 
necrosis factor alfa (TNFa), IL-22, interferon gamma (IFNγ), 
IL-6, IL-2 and IL-8 in order to propagate inflammation and 
induce keratinocyte hyperproliferation, ultimately leading to 
the development of mature psoriasis plaque.
Each of these pathogenetic mechanisms represent optimal 
target for highly specific therapeutical intervention being 
upstream events much better targets than downstream steps.
Figure 1 describes the different specific drugs targeting 
specific pathogenetic events.
Numerous biologics are approved by FDA or EMEA 
for the treatment of psoriasis, including an anti-CD11a 
antibody, namely efalizumab, and an anti-LFA3/CD2 
receptor, alefacept. In addition 3 TNFa agents (adalimumab, 
etanercept, infliximab) are now commercially available for 
the treatment of both psoriasis and psoriatic arthritis.
Alefacept
Alefacept (Amevive®, Biogen Inc.) is a fully humanized 
fusion protein composed from the first extracellular domain 
of LFA3 and the constant (CH2 and CH3) and hinge domain 
of IgG1. It binds to the natural ligand of LFA3, the CD2 
receptor (present on T lymphocytes), thus blocking the normal 
interaction between LFA3 and CD2 and, consequently, 
between antigen presenting cells and T lymphocytes. 
Moreover, because of its molecular structure, alefacept medi-
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cells expressing Fc-gamma receptor type IIIA, like natural 
killer (NK) cells: this leads to the recruitment of NK cells 
on alefacept binding CD2 positive T-cells leading to their 
apoptosis.19 Alefacept can be administered intramuscularly or 
intravenously, at the dosage of 15 mg per week and 7.5 mg 
per week, respectively
Alefacept was the first biologic agent approved by the 
US Food and Drug Administration for the treatment of 
moderate to severe plaque psoriasis20 and it is estimated that 
it has been used in more than 10,000 patients. Efficacy was 
firstly evaluated in two randomized, double-blind, placebo-
controlled phase III trials,21,22 which used intravenous and 
intramuscular administration, respectively.
efalizumab
Efalizumab is a recombinant, humanized monoclonal 
antibody that targets the alpha-subunit (CD11a) of the LFA1. 
By blocking the interaction of CD11a and of the intercellular 
adhesion molecule-1 (ICAM-1), efalizumab interferes at 
multiple levels with the pathogenesis of psoriasis, inhibiting 
leukocyte trafficking into the skin as well as the continuous 
activation of T-lymphocytes by antigen-presenting cells 
in the dermis and epidermis.23 Efalizumab is indicated 
for use in adults with moderate-to severe plaque psoriasis 
who are eligible for systemic therapy and considered as 
“high need” and is self-administrated by the patient once 
weekly by subcutaneous injection at the recommended dose is 
1 mg/kg/week.24,25 Several clinical trials have been performed 
with efalizumab, which validated its efficacy in short-term 
(12 weeks), mid-term (24 weeks) or long-term (36 or more 
months) treatment.26,27
Anti-TNFa agents
Etanercept
Etanercept is a dimer of a chimeric protein genetically 
engineered by fusing the extracellular, ligand binding 
domain of the human TNF receptor 2 and the Fc domain of 
human IgG1 antibody (including the hinge, CH2 and CH3 
regions but not the CH1 region).28 Because of its structure, 
etanercept binds and neutralizes the inflammatory cytokines 
TNF and lymphotoxin-alpha (TNFβ).29 Etanercept has been 
approved for the control of signs and symptoms, inhibiting 
radiographic progression and improving function in adults 
with psoriatic arthritis; it is also approved for moderate to 
severe plaque-type psoriasis. Etanercept is self-administrated 
subcutaneously, at a dosage regimen of 25 mg twice weekly 
or 50 mg once weekly (50 mg twice weekly can be used for 
the initial 12 weeks). Its efficacy and safety for the different 
dosings have been demonstrated in several randomized 
clinical trials.30–33 Pharmacokinetic modeling and simulation, 
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Figure 1 An overview of different pathogenetic steps of psoriasis and the specific drugs targeting each of these steps.
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as well as clinical studies, suggest that the systemic exposure 
is equivalent for the 25 mg twice weekly and the 50 mg once 
weekly regimens.34,35 However the 50 mg twice weekly dose 
seems to have stronger clinical activity. Current regulation 
allows using etanercept in 24-week courses.
Infliximab
Infliximab is a chimeric (25% mouse, 75% human) monoclonal 
IgG1 antibody able to bind TNFa (transmembrane and 
soluble form) and, consequently, to inhibit TNFa activity.36 
Infliximab was the first anti-TNFa therapy successfully 
used in psoriasis, in a woman affected also by refractory 
inflammatory bowel disease and therefore treated with 
infliximab 5 mg/kg.37 Several studies show that inflix-
imab acts on multiple steps of the pathogenetic process of 
psoriasis. Infliximab is approved for the treatment of psoriatic 
arthritis and plaque type psoriasis. Infliximab is administered 
intravenously, usually at the dose regimen of 5 mg/kg at 
weeks 0, 2, 6, and successively every 8 weeks. The efficacy 
and safety of infliximab has been evaluated in several clinical 
trials.36,38,39 Infliximab shows a fast efficacy in the treatment 
of plaque and arthritic psoriasis.
Adalimumab
Adalimumab is a fully human monoclonal antibody, 
genetically engineered using phage display technology, 
and it is structurally and functionally analogous to naturally 
occurring human immunoglobulins G1 (IgG1). This 
monoclonal antibody demonstrates a high specificity and 
affinity for TNFa but not other cytokines, such as lymphotoxin 
(LTβ).40 The recommended dosing of adalimumab for the 
treatment of plaque-type psoriasis and psoriatic arthritis is an 
initial dose of 80 mg, followed by 40 mg given every other 
week starting 1 week after the initial dose.41 The efficacy and 
safety of adalimumab has been evaluated in several clinical 
trials.42–45 Moreover adalimumab was the first biologic drug 
for which a comparative study with a conventional drug 
(methotrexate) has been performed.46
Role of interleukins 12 and 23 
in pathogenesis of psoriasis
Recent studies have demonstrated that IL-12 and IL-23 play 
an important role in the pathophysiology of psoriasis. Genetic 
polymorphisms in the genes that encode the shared p40 subunit 
of these cytokines (IL-12B), and one of the IL-23 receptor 
subunits that confer protection against Crohn’s disease47 has 
also been shown to confer protection against psoriasis.48 The 
p40 subunit of IL-12 and IL-23 is overexpressed in psoriasis 
plaques,49 and preclinical studies implicate p40-containing 
cytokines in the pathogenesis of psoriasis.50
These cytokines participate in immune function 
through activation of natural killer cells and CD4+ T-cell 
differentiation. IL-12 induces differentiation towards 
the T helper 1 (Th1) response and expression of type 1 
cytokines, such as IFNγ and TNFa, which are important in 
the pathophysiology of psoriasis.51–53 IL-23 induces differen-
tiation towards a T helper 17 (Th17) phenotype,54 expression 
of interleukin 17, and increased keratinocyte expression of 
inducible nitric oxide synthase, which has also been implicated 
in the pathophysiology of psoriasis.55,56 Cytokines produced 
by Th17 cells, including interleukin 20 and interleukin 22, 
have been implicated in the keratinocyte hyperproliferative 
response in psoriasis.57,58 Although the mechanisms by 
which IL-12 and IL-23 contribute to the pathophysiology of 
psoriasis are incompletely understood, the shared p40 protein 
might have a key role in the inflammatory cascade.59
Many current therapies used in the treatment of psoriasis 
modulate levels of IL-12 and IL-23, which are speculated 
to contribute to their efficacy,50 and agents that specifically 
target these cytokines improved psoriasis in early clinical 
trials.60–62
Ustekinumab
Ustekinumab (CNTO 1275, Centocor Inc, Malvern, PA, 
USA) is a human monoclonal antibody that binds to the 
shared p40 protein subunit of human IL-12 and IL-23 with 
high affinity and specificity, thereby preventing interaction 
with their surface IL-12Rβ1 receptor.63
Clinical studies
Different clinical studies have been conducted to date, in 
particular a phase I study, a phase II study and two phase III 
studies (PHOENIX 1 together with PHOENIX 2).
Phase I study
This was the first-in-human, non-randomized open-label 
study. The primary objective of this study was to evaluate 
the short-term efficacy, assess the pharmacokinetics, 
and determine the clinical response of single, ascending, 
intravenous (iv) administrations of anti-IL-12p40 in subjects 
with moderate to severe psoriasis vulgaris. Eighteen subjects 
with at least 3% body surface area involvement were enrolled 
in 4 dose groups (0.1, 0.3, 1.0, and 5.0 mg/kg). Safety, 
pharmacokinetics, and clinical response (eg, Psoriasis Area 
and Severity Index [PASI]) were monitored at baseline and at 
specific time points over a 16-week follow-up period. In this Clinical, Cosmetic and Investigational Dermatology 2009:2 99
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study noticeable clearing of psoriatic plaques was observed 
as early as 2 weeks following the study agent administration, 
with maximal therapeutic benefit achieved at 12 weeks for the 
majority of the subjects. In particular 12 of the 18 subjects 
(67%) achieved at least a 75% improvement in the PASI score 
between 8 and 16 weeks after the study agent administration. 
Both the rate and extent of the clinical response across the 
four dose groups was dose dependent. Moreover the drug 
was well tolerated and no treatment-related serious adverse 
events or adverse events requiring discontinuation or dose 
reduction were reported in this study.
In conclusion, this clinical study has provided the 
first information on the safety, pharmacokinetics, and 
clinical response of a single iv administration of anti-
IL-12p40 in human subjects with moderate-to-severe plaque 
psoriasis.60
Phase II study
In this double-blind, parallel group, placebo-controlled 
trial the safety and efficacy of single and multiple doses of 
the IL-12/23 monoclonal antibody (CNTO 1275) for the 
treatment of psoriasis was evaluated. A total number of 
320 patients with moderate to severe plaque psoriasis have 
been enrolled. With the use of adaptive treatment allocation 
based on a biased-coin minimization algorithm, patients 
were randomly assigned to one 45-mg subcutaneous dose 
of the IL-12/23 monoclonal antibody, one 90 mg dose, 
4-weekly 45 mg doses, 4-weekly 90 mg doses, or placebo. 
Randomization was stratified by investigational site and 
by the weight of the patient relative to 95 kg. At week 16, 
patients with a physician’s global assessment (termed 
PGA) of less than excellent (3 on a scale on which 1 is 
best and 6 is worst) received one additional injection of 
their originally assigned dose. At week 20, patients in the 
placebo group crossed over to receive one 90-mg injection 
of the IL-12/23 monoclonal antibody. Efficacy evaluations 
were performed through week 32. The primary end point 
was the proportion of patients achieving PASI 75 at week 
12 and the analysis was performed in an intention to treat 
basis to include data from all patients who had undergone 
randomization.
At week 12 (primary end point), PASI 75 was achieved 
in 52% of the patients who received one 45 mg dose of 
the interleukin-12/23 monoclonal antibody, in 59% of 
those who received one 90 mg dose, in 67% of those 
who received 4-weekly 45 mg doses and in 81% of 
those who received 4-weekly 90 mg doses, as compared with 
2% of those who received (p  0.001 for each comparison), 
moreover PASI 90 was achieved in in 23%, 30%, 44% and 
52%, respectively, of patients who received the monoclonal 
antibody as compared with 2% of patients who received 
placebo (p  0.001 for each comparison).
Adverse events occurred in 79% of the patients treated 
with the IL-12/23 monoclonal antibody as compared with 72% 
of the patients in the placebo group. Serious adverse events 
occurred in 4% of patients who received the monoclonal 
antibody and in 1% of those who received placebo.
This study has demonstrated the therapeutic efficacy of 
an IL-12/23 monoclonal antibody in psoriasis, providing 
further evidence of a role of the IL-12/23 p40 cytokines in 
the pathophysiology of psoriasis. The authors suggested 
that larger studies are needed to determine whether serious 
adverse events might limit the clinical usefulness of this new 
therapeutical target.61
PHOENIX 1
This was a phase III, double-blind, placebo-controlled, 
multicenter trial in which a total of 766 patients with moderate 
to severe psoriasis were enrolled. These patients were at least 
18 years old, with a diagnosis of plaque psoriasis for at least 
6 months, candidates for phototherapy or systemic therapy, 
with a PASI score of 12 or higher at baseline and with at 
least 10% body surface area involvement. Patients with a 
history or symptoms of active tuberculosis were excluded 
from the study; however, those with latent tuberculosis 
(a positive Mantoux tuberculin skin test without radiological 
evidence of tuberculosis) could be enrolled if treatment for 
latent tuberculosis according to local country guidelines for 
immunocompromised patients was initiated either before or 
simultaneous to the first administration of study agent.
This study was divided in 3 phases: a placebo-controlled 
phase (weeks 0–12), a placebo-crossover and active treat-
ment phase (weeks 12–40), and a randomized withdrawal 
phase (weeks 40–76). The safety and efficacy of ustekinumab 
were assessed over these three periods. At baseline, patients 
were randomly assigned in equal proportions to receive 
subcutaneous injections of ustekinumab 45 or 90 mg at 
weeks 0 and 4 and every 12 weeks thereafter or placebo 
at weeks 0 and 4, with half randomized to crossover to 
ustekinumab 45 mg and half to ustekinumab 90 mg at week 
12. At week 40, patients who had initially been randomized 
to receive ustekinumab who achieved long-term response 
(at least 75% improvement from baseline in PASI score 
[PASI 75] at weeks 28 and 40) were re-randomized to 
continue maintenance treatment with ustekinumab or 
were withdrawn from active treatment (placebo). Patients Clinical, Cosmetic and Investigational Dermatology 2009:2 100
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withdrawn from treatment at week 40 were re-treated when 
they lost at least 50% of PASI improvement. Patients not 
achieving PASI 75 at week 28 or 40 were not re-randomized, 
and their dosing was discontinued or modified. Baseline 
randomization was stratified by investigational site, weight 
(90 kg or 90 kg), and the number of conventional 
systemic therapies to which patients had an inadequate 
response, intolerance, or contraindication (3 or 3). Week 
40 randomization was stratified by investigational site and 
baseline weight (90 kg or 90 kg).
The primary efficacy endpoint was the proportion of 
patients achieving PASI 75 at week 12. Major secondary 
endpoints included: the proportion of patients with a 
physician’s global assessment score of cleared or minimal 
at week 12; the change in dermatology life quality index 
from baseline at week 12; and, in the randomized withdrawal 
phase, time to loss of PASI 75 response in the group 
receiving maintenance ustekinumab compared with the group 
withdrawn from treatment at week 40. About two-thirds of 
patients in each group were men. On average, patients had a 
20-year history of psoriasis and about a quarter of their body 
surface area affected by psoriasis. Over 90% of patients had 
used topical treatments previously, and at least 50% each 
had previously used conventional systemic or biological 
therapies.
All randomized patients were included in the efficacy 
analysis. 171 (67.1%) patients receiving ustekinumab 
45 mg, 170 (66.4%) receiving ustekinumab 90 mg, 
and 8 (3.1%) receiving placebo achieved PASI 75 at 
week 12 (difference in response rate vs placebo 63.9%, 
95% CI 57.8–70.1, p  0.0001 for 45 mg and 63.3%, 
95% CI 57.1–69⋅4, p  0.0001 for 90 mg). Moreover 
PASI 90 score was achieved in 42%, 37% and 2% of 
patients treated with ustekinumab 45 mg, 90 mg and 
placebo respectively. At week 40, long-term response had 
been achieved by 150 patients in the 45 mg group and 
172 patients in the 90 mg group. Of these, 162 patients 
were randomly assigned to maintenance ustekinumab and 
160 to withdrawal. PASI 75 response was better main-
tained to at least 1 year in those receiving maintenance 
ustekinumab than in those withdrawn from treatment at 
week 40 (p  0.0001 by log-rank test). During the placebo-
controlled phase, adverse events occurred in 278 (54.5%) of 
the 510 patients receiving ustekinumab and 23 (48.2%) of 
the 255 receiving placebo. Serious adverse events occurred 
in 6 (1.2%) of 510 patients receiving ustekinumab and 
in 2 (0⋅8%) of 255 receiving placebo in this phase. The 
pattern of adverse events was much the same in the placebo 
crossover and randomized withdrawal phases as it was in 
the placebo-controlled phase.
This study has concluded that ustekinumab seems to be 
efficacious for the treatment of moderate to severe psoriasis 
and that dosing every 12 weeks maintains efficacy for at least 
a year in most patients.63
PHOENIX 2
In this multicenter, phase III, double-blind, placebo-
controlled study a total number of 1230 patients with 
moderate-to-severe psoriasis were enrolled. The inclusion 
criteria were the same as in the PHOENIX 1 study. The study 
was divided into a placebo-controlled phase (weeks 0–12), a 
placebo crossover and active treatment phase (weeks 12–28), 
and a randomized dose intensification phase (weeks 28–52). 
The patients were randomly assigned to receive ustekinumab 
45 mg (n = 409) or 90 mg (n = 411) at weeks 0 and 4, then 
every 12 weeks, or placebo. Partial responders (ie, patients 
achieving 50% but 75% improvement from baseline in 
PASI) were re-randomized at week 28 to continue dosing 
every 12 weeks or escalate to dosing every 8 weeks. The 
baseline randomization was stratified by investigational 
site, weight (90 kg or 90 kg), and whether the patient 
had an inadequate response, intolerance, or contraindication 
to less than 3 or more than 3 conventional systemic thera-
pies. The primary efficacy endpoint was the proportion of 
PASI 75 responders at week 12. Major secondary endpoints 
were the proportion of patients with a physician’s global 
assessment score of cleared or minimal at week 12, change 
in dermatology life quality index from baseline at week 12, 
and, in the re-randomized partial responders, the number of 
visits with PASI 75 response between weeks 40 and 52 in 
the group receiving study drug every 8 weeks compared with 
the group receiving the drug every 12 weeks. Analyses were 
by intention to treat.
All randomized patients were included in the efficacy 
analysis. 273 (66.7%) patients receiving ustekinumab 
45 mg, 311 (75.7%) receiving ustekinumab 90 mg, and 15 
(3.7%) receiving placebo achieved the primary endpoint 
(difference in response rate 63.1%, 95% CI 58.2–68⋅0, 
p  0⋅0001 for the 45 mg group vs placebo and 72.0%, 
67.5–76.5, p  0⋅0001 for the 90 mg group vs placebo). More 
partial responders at week 28 who received ustekinumab 
90 mg every 8 weeks achieved PASI 75 at week 52 than 
did those who continued to receive the same dose every 
12 weeks (22 [68.8%] vs 11 [33.3%]; difference in response 
rate 35.4%, 95% CI 12.7–58⋅1, p = 0.004). There was no 
such response to changes in dosing intensity in partial Clinical, Cosmetic and Investigational Dermatology 2009:2 101
Ustekinumab for psoriasis Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
responders treated with ustekinumab 45 mg. During the 
placebo-controlled phase, 217 (53.1%) patients in the 45 mg 
group, 197 (47.9%) in the 90 mg group, and 204 (49.8%) 
in the placebo group experienced adverse events; serious 
adverse events were seen in 8 (2.0%) patients in the 45 mg 
group, 5 (1.2%) in the 90 mg group, and 8 (2⋅0%) in the 
placebo group.
This study has concluded that although treatment with 
ustekinumab every 12 weeks is effective for most patients 
with moderate-to-severe psoriasis, intensification of dosing 
to once every 8 weeks with ustekinumab 90 mg might 
be necessary to elicit a full response in patients who only 
partially respond to the initial regimen.64
Discussion
The use of a single cytokine as a potential target of 
antipsoriatic treatment has been widely validated with the 
success of the anti-TNFa therapies. In fact fusion proteins 
(etanercept) or antibodies (inliximab, adalimumab) blocking 
this cytokine have been shown to exert a potent antipsoriasic 
activity. Based on this fact and taking into consideration 
the different pathogenetic steps of psoriasis, other master 
cytokines with therapeutic potential for psoriasis may be 
used. One such candidate is a member of the IL-12 family 
of heterodimeric proteins sharing the p40 chain, as the 
blocking of the ILp40/IL-12Rβ1 interaction prevents the 
biological activity of IL-12 and IL-23, so interfering with 
the pathogenetic Th1 and Th17 environment in psoriasis. 
In fact members of the IL-12 family of cytokines have the 
potential to act as the next major cytokine(s) in pathogenesis 
and the treatment of psoriasis.59
The encouraging results presented in the above-mentioned 
studies regarding the use of ustekinumab for the treatment 
of psoriasis support the notion that IL-12 and IL-23 have a 
role in the immunopathophysiology of psoriasis.
Treatment with two 45 or 90 mg injections of ustekinumab 
at week 0 and week 4, followed by dosing every 12 weeks, led 
to PASI 75 response in more than three quarters of patients 
with moderate to severe psoriasis in both PHOENIX 1 and 
PHOENIX 2. In fact more than 90% of patients experienced 
clinically meaningful improvements, while the PHOENIX 2 
study further characterized determinants of treatment 
resistance as well as potential therapeutic approaches for the 
treatment-resistant subpopulation.63,64 Clinical improvements 
were also associated to improvements in patient-reported 
outcomes, measured by dermatology life quality index.
Onset of response was seen within 2 weeks of the first 
dose of ustekinumab, and psoriasis response was generally 
maintained for at least a year and a half in patients who 
received the drug every 12 weeks. The maintenance of efficacy 
between longer dosing intervals may be due to the fact that 
the pharmacodynamic effects of ustekinumab are longer 
than its pharmacokinetic effects. In patients withdrawn from 
ustekinumab, psoriasis gradually recurred – showing that 
temporary blockade of IL-12 and IL-23 did not reverse the 
underlying causal mechanisms of psoriasis – and quality-of-
life improvements were lost. Combined, these observations 
suggest that maintaining response and quality-of-life 
improvements could require continuous maintenance dosing. 
Among patients withdrawn from ustekinumab, response was 
generally restored within 12 weeks of reinitiating treatment.
In conclusion the results of different clinical studies 
suggest that ustekinumab could be an important therapeutic 
agent for treating patients with psoriasis. The high level 
of efficacy of ustekinumab was generally maintained with 
dosing every 12 weeks, a schedule that could offer a novel 
level of convenience for patients and physicians. These 
attributes might be particularly important for treatment 
compliance, which is low in patients with psoriasis and could, 
at least in part, result from dissatisfaction with effectiveness 
or convenience of available treatments.65,66
Nevertheless more studies are needed in order to evaluate 
the efficacy of ustekinumab also for the treatment of psoriatic 
arthritis, as joint involvement may be associated with the skin 
condition (in 5% to 42% of the patients).5
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